In rats, the drug has been found to possess strong local Antiandrogen activity,
but negligible systemic Antiandrogen activity when administered via subcutaneous injection.
Cortexolone 17α-propionate is a synthetic steroidal Antiandrogen- specifically,
an androgen receptor antagonist- that is under development by Cassiopea and Intrepid Therapeutics for use as a topical medication in the treatment of androgen-dependent conditions including acne vulgaris and androgenic alopecia(male-pattern hair loss).